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Abstract
The Hippo pathway is a signaling cascade recently found to play a key role in tumorigenesis therefore understanding the
mechanisms that regulate it should open new opportunities for cancer treatment. Available data indicate that this pathway
is controlled by signals from cell-cell junctions however the potential role of nuclear regulation has not yet been described.
Here we set out to verify this possibility and define putative mechanism(s) by which it might occur. By using a luciferase
reporter of the Hippo pathway, we measured the effects of different nuclear targeting drugs and found that chromatin-
modifying agents, and to a lesser extent certain DNA damaging drugs, strongly induced activity of the reporter. This effect
was not mediated by upstream core components (i.e. Mst, Lats) of the Hippo pathway, but through enhanced levels of the
Hippo transducer TAZ. Investigation of the underlying mechanism led to the finding that cancer cell exposure to histone
deacetylase inhibitors induced secretion of growth factors and cytokines, which in turn activate Akt and inhibit the GSK3
beta associated protein degradation complex in drug-affected as well as in their neighboring cells. Consequently,
expression of EMT genes, cell migration and resistance to therapy were induced. These processes were suppressed by using
pyrvinium, a recently described small molecule activator of the GSK 3 beta associated degradation complex. Overall, these
findings shed light on a previously unrecognized phenomenon by which certain anti-cancer agents may paradoxically
promote tumor progression by facilitating stabilization of the Hippo transducer TAZ and inducing cancer cell migration and
resistance to therapy. Pharmacological targeting of the GSK3 beta associated degradation complex may thus represent a
unique approach to treat cancer.
Citation: Basu D, Reyes-Mu´gica M, Rebbaa A (2013) Histone Acetylation-Mediated Regulation of the Hippo Pathway. PLoS ONE 8(5): e62478. doi:10.1371/
journal.pone.0062478
Editor: Ali J. Marian, The University of Texas Health Science Center, United States of America
Received January 15, 2013; Accepted March 21, 2013; Published May 6, 2013
Copyright:  2013 Basu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by startup funds from the University of Pittsburgh. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: abr25@pitt.edu
Introduction
The Hippo pathway is a novel signaling cascade first reported to
play a key role in regulation of organ size [1,2,3,4,5]. It was
identified in Drosophila through screening for genes whose loss of
function leads to tissue overgrowth, which resulted in identification
of warts, also called lats, as a gene associated with the most
pronounced phenotype [6]. Subsequent studies indicated that loss
of Warts/Lats accelerates cell cycle progression and inhibits apoptosis
[7,8,9] suggesting that this gene may have a tumor suppressor
function. During the last few years, several upstream and
downstream mediators of the Hippo pathway have been identified
including NF2, RASSF, MOB, MST1/2, WW45, 14-3-3, YAP,
TAZ and TEAD [1] and the list is still growing [10]. Core
components of the Hippo kinase cascade (Mst/Lats) are conserved
in mammalian genomes and have been shown to act in tandem
with casein kinase 1 epsilon (CK1e) to induce phosphorylation-
mediated inhibition of the Hippo transducers YAP, TAZ and
TEAD [11,12]. It was shown for instance that phosphorylation of
Hippo transducers facilitates their binding to14-3-3 and subse-
quent cytoplasmic sequestration [13,14,15]. Other studies have
demonstrated that sequential phosphorylation and degradation of
TAZ is facilitated by GSK3 beta/CK1e [16,17] suggesting that
alternative mechanisms of regulation may exist. As a result of these
perturbations, several biological processes, including cell-fate
determination [18], mitosis [19], and pluripotency [20] could be
affected. Of particular interest, deregulation of the Hippo pathway
was found to be associated with carcinogenesis [21]. This is best
illustrated by studies in which lats1 knockout in mice led to soft
tissue sarcomas and ovarian stromal cell tumors [22]. Moreover,
expression of TAZ showed an exceptionally strong association
with poor patient survival from non-small lung cancer and thyroid
carcinoma [23,24]. Alterations in this gene and/or its molecular
partners YAP and TEAD have also been reported in cancers
derived from colon, lung, liver or esophagus [25,26,27]. The
underlying mechanisms by which expression of Hippo transducers
facilitate tumor progression are not fully understood however
available data indicate that they may act in conjunction with
components of Wnt and/or TGF beta signaling pathways
[28,29,30] to induce certain cancer stem cell related processes
such as epithelial to mesenchymal transition (EMT) and the
development of resistance to therapy [31,32,33].
Based on the demonstrated role of Hippo signaling in cancer
progression, approaches to alter its activity may prove to be
effective for therapy, however for this to be achieved, prior
understanding of the mechanisms that regulate this pathway is
critical. Genes implicated in cell-cell interaction are thought to
represent major regulators of the Hippo signaling. In fact,
mutations of such genes in Drosophila, recapitulate the Hippo
phenotype [34,35] and increased phosphorylation and cytoplasmic
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sequestration of YAP was observed when cultured mammalian
cells reach confluency and begin to establish inter-cellular cell
contacts [11]. Conversely, disruption of cell–cell junctions resulted
in increased nuclear localization of both YAP and TAZ [30].
Interestingly, other membrane components such as the G-protein
coupled receptors (GPCRs), with no major role in cell-cell
interaction, have also been shown recently to regulate Hippo
signaling [36,37], highlighting the multifactorial aspect of this
regulation. While most of research effort up to now was directed
towards defining the role of plasma membrane associated
molecules in regulating the Hippo pathway, the possibility of its
nuclear regulation has not yet been described. Here we set out to
verify this possibility and define putative mechanism(s) by which it
might occur. Potential consequences of such regulation on cancer
cell migration and resistance to therapy, and the role of targeting
key components of the Hippo pathway to suppress these processes
are also addressed.
Materials and Methods
Human melanoma (WM115 and WM266), breast cancer
(MCF-7), and colon cancer (SW480) cell lines were purchased
from ATCC (Rockville MA). The 293 kidney cells were obtained
from Clontech (Mountain View, CA). Dulbecco’s Modified Eagle’s
Medium (DMEM), MEM, RPMI, Horse serum and fetal bovine
serum (FBS) were obtained from BioWhittaker (Walkersville, MD).
The following drugs and reagents were obtained from the
companies cited: The 8xGTII luciferase reporter construct [33]
from Addgene (Cambridge, MA); Doxorubicin, and antibody to
beta-Actin from Sigma-Aldrich (St. Louis, MO); CTGF, IL8,
Wnt3a from (R&D Systems, Minneapolis, MN); Antibodies to
Zeb1and Twist1 from Santa Cruz (Santa Cruz, CA), Vimentin
and N-cadherin from Cell Signaling Technology (Danvers, MA);
secondary antibodies conjugated to horseradish peroxidase from
Jackson Immunoresearch Lab Inc. (West Grove, PA); Enhanced
chemiluminescence reagents (ECL) and Immobilon-P transfer
membrane for Western blots from Millipore (Bedford, MA).
Reagents for DNA transfection were obtained from Life Tech-
nologies (San Diego, CA).
Cell Culture and Transfections
Melanoma and breast cancer cells were cultured in MEM
supplemented with 10% FBS as described by the supplier. Colon
cancer cells were maintained in RPMI supplemented with 10%
FBS, and the 293 cells were cultured in DMEM supplemented
with 10%FBS penicillin/streptavidin and non-essential aminoa-
cids (Life Technologies, San Diego, CA). Transfections were
carried out in 6 well plates using a lipofectamine kit (Life
Technologies, San Diego, CA) as described by the manufacturer.
Briefly, 3 mg of DNA were mixed in 100 ml of transfection solution
containing 90 ml of serum free culture medium and 10 ml
lipofectamine. After 20 min incubation at room temperature, the
mixture was added to the wells and incubated for 5 hours. The
medium was then replaced with a new one before the inhibitors
were added to the corresponding wells and incubated for an
additional 24 hours. Protein extracts were harvested and processed
for either Western blot or luciferase assay as described below.
Western Blot
Proteins were extracted from cells cultivated in monolayers
using 100 ml of lysis buffer (50 mM HEPES pH 7.4, 150 mM
NaCl, 100 mM NaF, 1 mM MgCl2, 1.5 mM EGTA, 10%
glycerol, 1% Triton X100, 1 mg/ml leupeptin, 1 mM phenyl-
methyl-sulfony l-fluoride). For nuclear and cytoplasmic fraction-
ation [38], cells were re-suspended in 400 ml of buffer A (10 mM
HEPES pH 7.9; 10 mM KCl;0.1 mM EDTA; 0.1 mM EGTA;
1 mM DTT; 0.5 mM PMSF). The mixture was incubated for
30 min on ice, then 25 ml of a 10% solution of Nonidet NP-40 was
added and the homogenate centrifuged for 30 sec. Equal
quantities of protein were separated by electrophoresis on a 12%
SDS-PAGE gel and transferred to Immobilon-P membranes.
Proteins of interest were identified by reaction with specific
primary and secondary antibodies linked to horseradish peroxi-
dase and detected by chemiluminescence.
Q-PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen,
Santa Clarita, CA).The first-strand cDNA was synthesized
according to manufacturer’s instructions using ThermoScript
RT-PCR system (Life Technologies, San Diego, CA). Gene
expression was measured by real-time PCR using the Maxima
Syber green Master Mix (Fermentas, Glen Burnie, MA) on ABI
7500 instrument (Applied Biosystems, Carlsbad, CA). Q–PCR
primers are reported in Table 1. Gene expression was normalized
to that of GAPDH used as internal control.
TEAD Activity Assay
The 86GTIIC-luciferase reporter which contains 8 TEAD
binding sites was used to measure activation of the Hippo
pathway. To evaluate the specificity of this reaction, we used a
DNA construct containing luciferase driven by the CMV
promoter as a control. These plasmids were transfected transiently
into cells using the lipofectamine kit as follows: 3 mg of DNA were
mixed in 100 ml of transfection solution containing 90 ml of serum
free culture medium and 10 ml lipofectamine. After 20 min
incubation at room temperature, the mixture was added to the
wells and incubated for 5 hours. The medium was then replaced
with a new one before the inhibitors or conditioned medium (CM)
from cells exposed to drugs were added to the corresponding wells.
After incubation for an additional 24 hours, the cells were lysed
and protein extracts used as a source of luciferase. For each test,
the luminescence value of CMV driven luciferase was substracted
Table 1. Primers used in Q-PCR.
Gene Forward primer 59–39 Reverse primer 59–39
Wnt3A CCTGCACTCCATCCAGCTACA GACCTCTCTTCCTACCTTTCCCTTA
Wnt4 GATGTGCGGGAGAGAAGCAA ATTCCACCCGCATGTGTGT
Wnt 7B CCCGGCAAGTTCTCTTTCTTC GGCGTAGCTTTTCTGTGTCCAT
Wnt 10A GGCAACCCGTCAGTCTGTCT CATTCCCCACCTCCCATCT
EGF CAGGGAAGATGACCACCACT TTCCCACCACTTCAGGTCTC
IGF1 CCCCACTCACCAACTCATAG GGTATTTGGGGCCTTTATGT
IL1a ATCAGTACCTCACGGCTGCT TGGGTATCTCAGGCATCTCC
SMA AGTTACGAGTTGCCTGATGG GAGGTCCTTCCTGATGTCAA
FGF23 TGGGTTAGGTTTTCTGTGGA AAGAATTTCCAAGGGGATTG
IL-6 ATGCAATAACCACCCCTGAC GAGGTGCCCATGCTACATTT
IL-8 TAGCAAAATTGAGGCCAAGG AGCAGACTAGGGTTGCCAGA
CTGF TTTGGCCCAGACCCAACTAT GTGCAGCCAGAAAGCTCAAA
TGF-b2 AACAAGAGCAGAAGGCGAAT TGCCATCAATACCTGCAAAT
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG
doi:10.1371/journal.pone.0062478.t001
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from the one obtained with 86GTIIC-luciferase. In control
samples, this difference is considered as 100% of activity.
Collection of Conditioned Medium (CM)
Near confluent cultured WM 115 melanoma cells grown in
25 cm2 flasks containing MEM and 10% FBS at 37uC in 95% air/
5% CO2, were exposed to Belinostat at 10
26 M for 24 hours. The
cell monolayer was then washed three times and placed in fresh
medium for 2 hours to allow elimination of intracellular Belinostat.
The cells were then placed in 5 ml of new MEM for an additional
24 hours to allow secretion of soluble factors. The medium was
harvested and centrifuged at 10006g for 10 min to remove
residual cells and debris. The supernatant was collected and used
as conditioned medium (CM) containing Belinostat-induced
secreted factors.
MTT Assay
Cells were incubated in a 96 well plate with the drugs for 96 h.
The fraction of viable cells were quantitatively determined by a
colorimetric MTT assay as described previously [39]. MTT (10 ml
of 5 mg/ml solution) was added to each well of the titration plate
and incubated for 4 h at 37uC. The cells were then solubilized by
the addition of 100 ml of 10% SDS/0.01 M HCl and incubated for
15 h at 37uC. The optical density of each well was determined in
an ELISA plate reader using an activation wavelength of 570 nm
and reference wavelength of 650 nm. The percentage of viable
cells was determined by comparison with untreated control cells.
Statistical Analysis
Graph data is presented as mean 6 standard error (SE). All
analyses were performed by using a 2-way ANOVA and values in
the treated samples were compared to the corresponding controls.
P,0.05 was considered statistically significant. Statistical calcula-
Figure 1. Respective roles of DNA damage and chromatin modification in regulation of the Hippo pathway. Panel A. Hippo reporter
activity in response to drugs tested at concentrations that induce 50% inhibition of proliferation in SW480 cells (indicated at the top of each bar). Ctl:
control., Cisp: cisplatin., Dox: doxorubicin., Bel: Belinostat., TSA: Trichostatin A., AZA: 5 Azacitidine(decitabine)). Panel B. Western blot showing the
effect of Belinostat on acetylation of Histone H3 at Lysine 9 (H3K9) (Upper level), and activity of Hippo reporter in MCF7 and WM 266 melanoma cells.
Each bar in Panels A and B represents the average of three determinations 6SE. Statistical significance is shown for drug-treated cells compared to
the corresponding untreated controls (*p,0.05, **p,0.001). Panel C. Western blots depicting the effect of Belinostat on expression and/or
phosphorylation of various components of the Hippo pathway in SW480 cells. Panel D. Expression of TAZ in MCF7 and WM 266 cells in response to
Belinostat. Panel E. Representative data showing the effect of siRNA mediated Knockdown of HDAC1 on expression of TAZ in WM266 cells measured
by Western blot.
doi:10.1371/journal.pone.0062478.g001
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tions were performed with SPSS 16.0 for Windows (SPSS,
Chicago, IL, USA).
Results
Respective Roles of DNA Damage and Chromatin
Modification in Regulation of the Hippo Pathway
The effects of DNA and chromatin modulating drugs on activity
of the Hippo pathway were analyzed using the (86GTII) luciferase
reporter system [33] in which a DNA binding sequence for TEAD
drives expression of the luciferase gene. For this, HEK 293 cells
were transfected with this construct and exposed to the DNA
damaging drugs doxorubicin, cisplatin and 5FU, the DNA
methyltransferase inhibitor 5 AzaC, or histone deacetylase
inhibitors TSA and Belinostat, each at a concentration that
induce 50% inhibition of cell proliferation. As shown in Figure 1A,
the DNA de-methylating agent 5 AzaC has no effect on TEAD
reporter activity, however the DNA damaging agents doxorubicin,
cisplatin and 5-FU exerted a relatively moderate stimulation (up to
2.5 times increase). In contrast, both histone deacetylase inhibitors
Belinostat and TSA induced strong activation of the TEAD
reporter. Stimulation of the luciferase activity in response to
Belinostat was concentration dependent and correlated with the
levels of histone acetylation induced by this drug (Fig. 1B). The
effect of Belinostat was also valid in other cell lines (Fig. 1 B)
suggesting that this observation may represent a general phenom-
enon.
To gain insight on potential molecular mediators, we measured
expression and phosphorylation levels of various intracellular
mediators of Hippo signaling and as shown in Figure 1C, neither
expression of Mst1 and Lats1, nor their phosphorylation levels
changed significantly. Unexpectedly, phosphorylation of YAP
decreased in response to increased concentrations of Belinostat,
which could be explained by decreased expression of this gene as
Figure 2. Regulation of Hippo downstream genes by Belinostat and role of TAZ in mediating these effects. Panel A. Expression of TAZ
target genes CTGF and Cyr61 measured by Q-PCR in the absence or the presence of Belinostat at the indicated concentrations (mM). Panel B.
Representative Western blots showing the expression of EMT genes in response to Belinostat in SW480 cells (Ecad: E Cadherin, N-Cad: N cadherin).
Panel C. Effect of TAZ gene overexpression on activity of the Hippo reporter. SW480 cells were transfected with the TAZ DNA construct at the
indicated concentrations and activity of luciferase reporter measured after 24 hrs. Panel D. Effect of TAZ overexpression on expression of its
downstream target genes. Cells were transfected by TAZ as described in panel C and expression of CTGF and Cyr 61 and Vimentin (Vim) was
measured by Q-PCR. Panel E. Representative Western blots showing expression of EMT associated genes in response to TAZ overexpression (Vim:
Vimentin, N-Cad: N cadherin). Data in panels A, C and D, represent average of three determinations 6SE. Statistical significance is shown for drug-
treated or TAZ-transfected cells compared to the corresponding controls (*p,0.05, **p,0.001).
doi:10.1371/journal.pone.0062478.g002
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noted in Figure 1C. Of particular interest, the levels of the Hippo
transducer TAZ increased in a drug concentration-dependent
manner in WM115 cells (Fig. 1C), as well as in other cell lines
(Fig. 1D). siRNA to HDAC1 resulted in increased levels of TAZ in
WM266 cells (Figure 1E) suggesting that this phenomenon is
histone acetylation-dependent.
Regulation of Hippo Downstream Genes by Belinostat
and Role of TAZ in Mediating these Effects
To better define the relationship between histone acetylation
and the Hippo pathway, we measured expression downstream
genes in response to Belinostat. The data presented in Figure 2A
indicate that expression of CTGF and Cyr61, two well-known
targets of TAZ [40], was strongly induced in the treated cells and
in a concentration dependent manner. Since the Hippo pathway
has been shown to signal for epithelial mesenchymal transition
Figure 3. Belinostat-induces stabilization rather than expression of TAZ. Panel A. expression of TAZ in response to Belinostat (5 mM)
measured quantitative PCR. Panel B. Effect of Belinostat on TAZ stabilization. SW480 cells were exposed to cycloheximide (CXH) at 10 mM
concentration in the absence or the presence of Belinostat (mM). Proteins were extracted at the indicated times after addition of the compounds and
TAZ protein levels determined by Western blot. Band densities were quantified by the Image J software (NIH) and graphed. Data in graphs A and B
represent average of three determinations 6SE. Significance (p,001) is shown in graph B between Belinostat-treated cells for 6 hours and the
corresponding non-treated cells. Panels C and D. SW480 cells were transfected with genes coding for CK1e or constitutively active GSK3 beta (GSK-S9)
and TAZ protein levels determined by Western blot after 48 hours. Panel E. Effect of Belinostat on phosphorylation of Akt and GSK3 beta. The cells
were exposed to the drug for 1hour in serum free medium and protein phosphorylation detected by Western blot using specific antibodies. Beta
actin is used as a loading control in panels B, C, D and E.
doi:10.1371/journal.pone.0062478.g003
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(EMT) through overexpression of TAZ [14,33], we determined if
expression levels of EMT genes are altered in response to
Belinostat and if so, whether overexpression of TAZ would be
sufficient for inducing such alterations. The results (Fig. 2B)
indicate that this was the case since the levels of Twist, snail,
Vimentin and N-Cadherin were all induced and this was
accompanied by a slight decrease of E cadherin in response to
Belinostat. Importantly, TAZ overexpression resulted not only in
enhanced TEAD reporter activity (Fig. 2C) and expression of its
target genes CTGF, Cyr61 (Fig. 2D) as it might be expected, but
also in induction of the same EMT genes induced by Belinostat
(Fig. 2E). Together, these findings suggest that cancer cell
exposure to histone deacetylase inhibitors may paradoxically
signal for cancer progression by facilitating EMT through
induction of TAZ and its downstream target genes.
Mechanism(s) by which Histone Acetylation Regulates
the Hippo Pathway
a) Induced expression versus stabilization of TAZ. To
determine if TAZ regulation by Belinostat occurs at the gene or
post-translational level, we first measured its expression using
quantitative PCR. No changes were however detected by either
technique (Fig. 3A), suggesting that the observed increase in levels
of this gene (Fig. 1C) was not due to enhanced RNA expression.
To determine if Belinostat inhibits TAZ degradation, protein
synthesis was inhibited using cycloheximide and a chase experi-
ment was carried out in the absence or the presence of the drug.
Figure 4. Potential role of G-protein coupled receptors in mediating Belinostat induced activation of the Hippo pathway. Panel A.
Effect of conditioned medium from Belinostat pre-exposed cells on activation of the Hippo reporter in naı¨ve cells (not previously exposed to the
drug). SW480 cells were incubated with Belinostat at the indicated concentrations for 24 hours, the drug was then washed extensively and the cells
incubated with fresh media for 24 hrs. The resulting conditioned media (CM) were then incubated for 24 hrs with naı¨ve cells transfected with the
Hippo luciferase reporter, after what the activity of the enzyme was determined. The data represent average of three determinations 6SE. Statistical
significance is shown for Bel-CM-exposed cells compared to the control (**p,0.001). Panel B. Representative Western blots showing the effect of CM
from Belinostat treated cells on expression of YAP and TAZ in naı¨ve cells. Beta actin was used as a loading control. Panel C. Effect of glucagon (Gln), a
GPCR antagonist, on Bel-CM induced activation of the Hippo reporter. SW480 cells transfected with the luciferase reporter were incubated in the
absence or the presence of CM from cells pre-exposed to 0.5 mM Belinostat (Bel-CM), and in the absence or the presence of glucagon at the indicated
concentrations. Luciferase activity was measured after 24 hrs of incubation. The data represent average of three determinations 6SE. For every Gln
concentration, values were compared between Bel-CM exposed cells and those exposed to control CM (**p,0.001). Panel D. Effect of Glucagon on
Belinostat-mediated increase in TAZ levels determined by western blot in cells exposed or not to Bel-CM and in the absence or presence of Gln at
5 mM. Staining with beta actin represents a loading control.
doi:10.1371/journal.pone.0062478.g004
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As shown in Figure 3B, TAZ was indeed degraded at a slower rate
in cells exposed to Belinostat compared to non-treated controls.
Since both GSK3 beta [16] and casein kinase 1ehave been shown
to play key roles in facilitating TAZ degradation, we sought to
determine which one of these two enzymes would be implicated.
The results indicate that overexpression of Casein kinase 1e had
only a minimal effect if any on TAZ levels (Fig. 3C), however
overexpression of the constitutively active form of GSK3 beta
Figure 5. Role of secreted growth factors and cytokines in mediating Belinostat-induced activation of the Hippo pathway. Panel A.
SW480 cells were incubated with the indicated concentrations of Belinostat for 24 hours and expression levels of selected secreted factors were
determined by QPCR and compared to those in control non-treated cells. Panel B. Effect of individual growth factors and cytokines on TAZ levels and
phosphorylation of GSK 3 beta. Cells were incubated with the indicated soluble factors (at 100 ng/ml each) for 24 hours and proteins extracted and
processed for western blot using specific antibodies to TAZ and phosphorylated GSK3 beta. Panel C. Effect of individual growth factors and cytokines
on activity of the Hippo reporter. Cells transfected with the reporter construct were incubated with the indicated factors for 24 hours and luciferase
activity measured as described in the Methods section. Each bar in Panels A and C represents the average of three determinations 6SE. Statistical
significance is shown for treated cells compared to the corresponding untreated controls (*p,0.05, **p,0.001).
doi:10.1371/journal.pone.0062478.g005
Chromatin-Mediated Regulation of the Hippo Pathway
PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e62478
(GSK3-S9) prevented TAZ stabilization (Fig. 3D). In support of
this, phosphorylation levels of both GSK 3 beta and its upstream
kinase Akt were induced by Belinostat (Fig. 3E). These findings
suggest that histone acetylation-mediated induction of TAZ occurs
at the post-translational level and may be caused at least in part by
inhibition of GSK3 beta associated degradation complex which is
known to prime proteins for proteasomal degradation [41].
b) Potential role of secreted factors in mediating the
effects of histone acetylation on TAZ transactivation. To
obtain further insights on the mechanisms by which histone
acetylation signals for the stabilization of TAZ, we analyzed the
potential role of secreted soluble factors which in an autocrine or
paracrine manner, could signal for inhibition of GSK3 beta
associated degradation complex, resulting in enhanced TAZ
accumulation. For this, we first determined if conditioned medium
from cells pre-exposed to Belinostat (Bel-CM) induces TEAD
reporter activity in naı¨ve cells (not previously exposed to the drug),
and the results indicate that this was indeed the case (Fig. 4A).
Stimulation levels obtained with Bel-CM (1.2 to 2.5 times) are
however lower than those obtained in cells directly incubated with
the drug (5 to 10 times, Fig. 1A and 1B), suggesting that a
continuous expression and secretion of these factors may be
required for higher and sustained reporter activity. Interestingly,
Bel-CM also inhibited YAP expression and enhanced TAZ levels
(Fig. 4B) in a manner that recapitulates the effects of Belinostat on
these two genes (Fig. 1B).
In light of recent evidence that G protein coupled receptors
(GPCRs) may play a key role in mediating the action of soluble
Figure 6. Targeting the GSK 3 beta associated destruction complex reduces TAZ levels, cancer cell migration and resistance to
therapy. Panel A. Naı¨ve SW480 cells were exposed to conditioned medium from Belinostat (1 mM) treated counterparts (Bel-CM), in the absence or
the presence of Pyrvinium (PYR) at 0.5 mM. After 24 hours, the cells were processed for Western blot with antibodies to TAZ, Vimentin (Vim) and beta
actin. Panel B. Monolayer scratch assay depicting the effect of Bel-CM on cell migration and its delay by pyrvinium. MCF cells cultured until confluency
and scratches introduces in the monolayer using a pipette tip. The cells were then incubated in the presence or absence of Bel-CM, with or without
pyrvinium (0.5 mM) for the indicated times, representative photographs are shown. Panel C. Effect of Bel-CM and pyrvinium of cellular response to
doxorubicin. SW480 cells were incubated with doxorubicin at the indicated concentration in absence or presence of Bel-CM, Pyrvinium (PYR) or both.
Cell viability was determined by MTT assay as described in the Methods section and the data represented as per cent of control non-treated cells. The
data represent average of three determinations 6SE. Statistical significance is shown for Bel-CM exposed cells in the absence or the presence of PYR
(**p,0.001). Panel D. Effect of PYR on cellular response to other drugs. Cells were exposed to the indicated drugs in the absence or presence of Bel-
CM (BCM) and pyrvinium (P). Cell viability was determined by MTT assay after 72 hours in culture. The data represent average of three determinations
6SE. Statistical significance is shown for Bel-CM exposed cells in the absence or the presence of PYR for each drug tested (*p,0.05, **p,0.001).
doi:10.1371/journal.pone.0062478.g006
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factors on the Hippo pathway [36,37], we determined if inhibition
of GPCR signaling by glucagon would reduce the effect of
Belinostat on Hippo signaling and TAZ levels. The results
presented in Figure 4C indicated that this was not the case and
to the contrary glucagon seemed to induce the Hippo reporter
activity. This, in addition to the observation that glucagon had no
effect on Bel-CM induced TAZ stabilization (Fig. 4D) suggests that
the GPCR pathway may not mediate the action of Belinostat on
Hippo signaling. Alternatively, the possibility that Belinostat
induces expression of growth factors and/or cytokines, which in
turn signal for inhibition of the GSK3 beta associated degradation
complex and cause stabilization of TAZ seemed plausible
(Figure 5A). Data in this figure indicate that exposure of
melanoma cells WM 115 to Belinostat resulted in expression of
various ligands, some of which are known for their ability to
activate Wnt [42], TGF beta [43] or the Hippo signaling pathways
[44,45]. As positive controls, levels of the two downstream genes of
Hippo pathway CTGF and Cyr61 increased dramatically (more
than 15 times). Others such as Wnt3a and IL8 were induced at
levels between 5 to 15 times, while IGF, TGF beta2, Wnt4, Wnt7,
Wnt10 and IL6 were induced 2 to 5 times (Fig. 5A). Individual
factors were tested for their ability to induce TAZ stabilization and
activation of the luciferase reporter and as indicated in Figure 5 B,
Wnt3a was the most effective in doing so, consistent with previous
reports that the corresponding pathway regulates Hippo signaling
[46]. IL8 also enhanced TAZ levels but to a lesser extent, while
CTGF, EGF and IGF had no effect in this cellular model perhaps
due to lack of expression of the corresponding receptors (Fig. 5B).
Interestingly, factors that increased TAZ levels also induced
phosphorylation of GSK3 beta, and activity of luciferase (Fig. 5B
and 5C) providing further support for the implication of this
enzyme in regulation of Hippo signaling.
Consequences on EMT, Cell Migration and Resistance to
Drugs and Potential Role of Targeting GSK3 Beta
Associated Degradation Complex in Suppressing these
Events
Tumor microenvironment is known to regulate cancer cell
migration and survival. Since most if not all of the secreted factors
described above have been reported to play a role in tumor
progression, the possibility exist that CM from cancer cells pre-
exposed to Belinostat (and thus enriched in these factors) will
induce phenotypic features of aggressive cancers such as enhanced
expression of EMT genes, cell migration and resistance to drugs.
In addition, the finding that GSK3 beta is implicated in histone
acetylation mediated transactivation of TAZ suggests that
pharmacological targeting of this enzyme or the associated
degradation complex should attenuate these effects. We tested
Figure 7. Schematic model depicting nuclear regulation of the Hippo pathway in drug-affected and neighboring cells. Exposure to
certain drugs affecting DNA or chromatin results in enhanced expression of secreted growth factors and cytokines. These secreted factors (SFs) may
in turn signal in autocrine/paracrine manner for activation of Akt and inhibition of GSK3 beta associated degradation complex (GSK3b/DC) resulting
in stabilization of TAZ oncogene. Consequently, expression of EMT genes is enhanced, leading to increased cell migration and drug resistance (DR) in
both drug affected and neighboring cells. These processes can be overcome by using pyrvinium (PYR), a pharmacological activator of GSK3 beta
associated degradation complex.
doi:10.1371/journal.pone.0062478.g007
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these possibilities first by measuring the effect of pyrvinium, a
known activator of the GSK3 beta associated degradation
complex [47], on the ability of Belinostat to stabilize TAZ and
induce the EMT gene Vimentin. As shown in Figure 6A, this
compound effectively reduced the level of both genes. In another
set of experiments, melanoma cells were exposed to CM from non-
treated or from Belinostat-treated counterparts (CM or Bel-CM
respectively) and analyzed the consequence of this on cell
migration and response to drugs. As shown in Figure 6B, cell
migration was accelerated upon exposure to Bel-CM however
pyrvinium suppressed it. Bel-CM exposed cells also survived better
doxorubicin-mediated toxicity (Fig. 6C) suggesting a protective
effect of this medium against chemotherapy. This resistance
phenotype is valid for other drugs and can be reversed if cancer
cells were pre-incubated with pyrvinium (Fig. 6C and 6D),
indicating that this type of compound may represent a useful
adjuvant to improve the anticancer activity of TAZ inducing
chemotherapeutics.
Overall, findings from this study shed light on a previously
unrecognized phenomenon by which certain anti-cancer agents, in
particular those that regulate histone acetylation, may paradox-
ically promote tumor progression by inducing expression of
secreted factors capable of stimulating the Hippo pathway and
thus facilitating cancer cell migration and resistance to therapy.
Since GSK3 beta associated degradation complex is implicated in
this process, pharmacological activators of this complex may
represent useful tools to improve the anticancer activity of TAZ
stabilizing stimuli.
Discussion
Loss of cell polarity is a hallmark of cancer [48] and activation
of the Hippo signaling pathway has emerged as a key regulator of
this process [49], suggesting that the associated pathway may
represent a compelling target for therapy. For this to be achieved
however, the molecular mechanisms that regulate Hippo signaling
need to be fully understood. Available data indicate that this
pathway is regulated by elements of tight-junctions [48] and G-
protein coupled receptors [36]. Here we provide evidence for an
additional site of regulation and show that signals from the
nucleus, in particular those resulting from changes in histone
acetylation may also regulate Hippo signaling. An example of such
stimuli is the histone deacetylase inhibitor Belinostat currently
used in the clinic to treat cancer [50]. Our findings indicate that
Belinostat causes the stabilization of the Hippo transducer TAZ
which is known for its oncogenic function and ability to induce
cancer stem cell characteristics [23,24].
The observation that among all stressors tested, inhibitors of
histone deacetylases had the most pronounced effects on activity of
the Hippo reporter (Fig. 1A) and expression of downstream target
genes is in line with the plastic nature of chromatin remodeling
and the reversibility of EMT, by comparison to DNA damage
which generally leads to a stable phenotype. Interestingly, the
effect of Belinostat on TAZ/TEAD reporter activity was not
caused by enhanced expression and/or activity of upstream Hippo
signaling intermediates such as the kinase core complex (Mst/
Lats), however, we noted that this drug induced a concentration-
dependent decrease in YAP and increase in TAZ levels in the
drug-treated cells (Fig. 2). The reduction of YAP is somewhat
intriguing nonetheless it represents a desirable outcome since this
gene is known to facilitate cancer progression [27,51]. In contrast,
enhanced TAZ levels in response to Belinostat (Fig. 2) is unwanted
for the same reason that this gene is also known to be associated
with worst prognosis [23,24]. Previous work from our laboratory
and others have shown that increased histone acetylation promotes
EMT, cancer metastasis [52,53] and resistance to therapy [54,55],
but the underlying mechanism(s) was not understood. Here we
show that TAZ may represent the principal mediator of these
events and since TAZ and not YAP has been shown to confer
cancer stem cell phenotype in breast cancer [33], the latter
transcription factor may be dispensable for mediating the pro-
EMT effects of HDAC inhibition.
Although histone acetylation is known to be associated with
increased gene expression, Belinostat had no effect on TAZ
mRNA levels (Fig. 3A). The data revealed that this drug acts on
the Akt/GSK3 pathway to prevent TAZ degradation, raising the
possibility that secretion of soluble factors which signal for
activation of Akt and subsequent inhibition of GSK3 may account
for Belinostat-mediated stabilization of TAZ. In support of this, we
show (Fig. 4A and 4B) that conditioned medium from cells pre-
treated with Belinostat activated the TAZ/TEAD reporter and
promoted TAZ stabilization. Apparently, the GPCR pathways
does not play a significant role in mediating the effect of Belinostat
on the Hippo pathway since cellular treatment with glucagon, a
GPCR antagonist, had no effect on TAZ levels or activity of the
corresponding reporter (Fig. 4C). We found however that
Belinostat-induced expression of several secreted growth factors
(Fig. 5A), some of which (i.e. Wnt 3a and IL8) are capable of
inducing activity of the Hippo reporter, phosphorylation-mediated
inhibition of GSK3 beta and stabilization of TAZ (Fig. 5B and
5C). These findings are in agreement with previous work that both
Wnt3a and IL8 signal through GSK3 beta complex [41,56] and
suggest that by integrating different signaling pathways, this
complex may represent a conceivable target to inhibit the pro-
tumorigenic function of TAZ stabilizing agents. The data also shed
light on an inter-cellular cytoprotective mechanism by which
histone deacetylase inhibitors activate the Hippo pathway not only
in drug affected cells, but also in those that are not directly
accessible to the drug. Such a bystander effect is demonstrated by
the ability of conditioned medium (Bel-CM) from drug-treated
cells, to induce expression of EMT genes and migration in cells not
previously exposed to it (Fig. 6A and 6B).
Besides metastasis, another cause of cancer recurrence is the
development of drug resistance. Over the years, we come to realize
that cancer cells have the ability to adapt and ultimately escape the
toxicity of virtually any drug tested so far. The underlying
mechanisms are numerous and some are well described, however
the initial steps leading to development of resistance are not yet
understood. In this regard, the finding that increased histone
acetylation may induce the development of drug resistance
provides a unique opportunity for exploring the causes of this
phenomenon in order to prevent its onset. This in addition to the
interesting observation that this process is mediated by the GSK3
beta associated degradation complex makes it pharmacologically
tractable, for instance by using the recently discovered activator
pyrvinium [47]. The data presented in Figure 6 provide proof of
concept for this and show that cancer cell exposure to pyrvinium
may suppress Belinostat-induced accumulation of TAZ, cell
migration and resistance to therapy. Together, findings from this
study shed light on a novel mechanism by which certain
chemotherapeutic drugs, particularly those that affect chromatin
integrity, signal for enhanced migration and survival of both drug
affected and neighboring cells (Fig. 7). Since GSK3 beta associated
degradation complex was found to play a key role in mediating
these events small molecules activators of this complex would
represent desirable tools to suppress cancer progression.
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Supporting Information
Data S1 Quatification of western blot staining from
Figure 1D. The band intensity was quantified using ImageJ
software (NIH). The data represent average of three determina-
tions 6SE. Significance reflects comparison between Belinostat-
treated cells and the corresponding non-treated cells (*p,0.05,
**p,0.001).
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